| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-09 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.28 | 7e-08 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.18 | 2e-07 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.21 | 2e-07 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-07 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.2 | 6e-07 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.18 | 7e-07 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | -0.17 | 1e-06 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-06 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.17 | 1e-06 |